Transforming diagnostic standards and drug development for
Nonalcoholic Steatohepatitis (NASH) with AI-based digital pathology
Founder of an AI-based digital pathology solution that
aids NASH clinical trials towards optimal outcomes
Working hand-in-hand with our collaborators to accelerate clinical research
and drug development efforts with unrivalled accuracy and sensitivity
Catch up on the latest medical advancements and research discoveries on Nonalcoholic Steatohepatitis (NASH) taking place across the globe.
We are committed towards enhancing the diagnosis of chronic liver conditions like nonalcoholic steatohepatitis (NASH), and accelerating the development of effective treatments.
Find Out MoreRevolutionizing tissue assessment with Second Harmonic Generation (SHG) and Two-Photon Excitation (TPE) to provide quantitative, objective and accurate data.
Find Out MoreWe have been recognised with several industry-renowned awards for our efforts and accomplishments in the core areas of our business, particularly medical technology and product innovation.
We are committed towards building strong and mutually rewarding partnerships with world-renowned medical, academic and research institutions as well as market leaders in the Life Sciences and Healthcare sectors.
Introducing our podcast/webinar series that will bring you insights from experts on the role of AI digital pathology in drug discovery for NASH.
Find Out More